Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. | Monopar Therapeutics ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give ...

After receiving a green light earlier this year from the FDA, Medtronic has now collected a European approval for the latest ...

After forming a gene therapy partnership with Dyno Therapeutics in 2020, Roche is back for more. | In a new deal potentially ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Lundbeck is slashing the book value of its $250 million Abide Therapeutics buyout in response to phase 1 data that triggered ...

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...

Massachusetts-based tech company Revvity has launched a new tool to remove a data entry chore from clinical laboratories. | ...

Alpha-9 Oncology has raised a $175 million series C round to bankroll its clinical-stage radiopharmaceutical drugs, although ...

Merck & Co. is putting down $30 million cash to buy Yale spinout Modifi Biosciences, a deal that includes a preclinical asset ...

Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...